Zhongyuan Investment
中源投资
elsewhere's corpus does not cover Zhongyuan Investment as a subject in its own right. The only mentions found are passing references in August 2025 coverage of Zenitar's nearly RMB 400 million Series B+ round, where Zhongyuan Investment (中源投资) is listed among the co-investors alongside Qiming Venture Partners, Gaorong Capital, Jifeng Capital, Qiji Investment, and 5Y Capital . No founding date, fund size, strategy, team, or other profile details appear in elsewhere's materials.
AI-generated — may contain errors, please verify.
Coverage
5Y News | Zai Ling Bio Completes Nearly RMB 400 Million Series B+ Round
Accelerating the buildout of an innovative drug pipeline built on differentiated molecular scaffolds and novel targets, with a commitment to addressing unmet clinical needs.
Zenitar Closes Nearly RMB 400 Million Series B+ Round, Multiple Global First-in-Class Drugs Enter Pivotal Clinical Trials
Structural Biology and AI-Driven Innovative Drug Discovery and Development
Zenitar Raises Nearly 400 Million Yuan in B+ Round Led by Qiming Venture Partners
Zenitar is a structure-based biology and AI-driven innovative drug R&D company, focused on unmet clinical needs in major therapeutic areas including oncology, autoimmune diseases, inflammation, and neurological disorders. The company is dedicated to discovering, developing, and commercializing first-in-class and best-in-class innovative medicines.
